NovoCure Limited (NASDAQ:NVCR – Get Free Report) shares gapped down before the market opened on Thursday after the company announced weaker than expected quarterly earnings. The stock had previously ...

NovoCure remains a strong buy with robust earnings, growth in cancer treatments, and significant upside potential to Wall ...

NovoCure's FDA approvals face adoption struggles despite growth. Read why NVCR stock may decline with slow indication ...

NovoCure Ltd (NVCR) reports a 21% revenue increase in Q4 2024, driven by FDA approvals and successful trials, despite facing ...

NovoCure Ltd. (($NVCR)) has held its Q4 earnings call. Read on for the main highlights of the call. NovoCure’s recent earnings call showcased a ...

Welcome to the NovoCure fourth-quarter 2024 earnings conference call. [Operator instructions] Please be advised that today's ...

NovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion.

瑞士巴尔 - 尽管收入超出预期，但由于第四季度收益未能达到分析师预期，肿瘤治疗公司Novocure（NASDAQ:NVCR）股价下跌6.3%。该公司在将其肿瘤治疗场（TTFields）疗法扩展到新适应症方面取得进展，但投资者似乎对超出预期的亏损表示担忧。 Novocure报告第四季度每股亏损-$0.61，较分析师预期的-$0.36低$0.25。然而，季度收入达到$161.26百万，超过了$153.

NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.

Marketing expert Anita Nevins, with over three decades of experience, has released her debut book, The Three C's of Marketing: Content, Communication, and Connection ? Strategies to Build a Following ...

英为财情Investing.com - Novocure (NASDAQ: NVCR )星期四发布了第四季度的财报，数据显示，公司营收高于分析师的预期，每股收益低于分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.61，总营收为$161.26M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$153.04M，每股收益为$-0.36.

ST. HELIER, Jersey (AP) — ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Thursday reported a loss of $65.9 million in its fourth quarter. The St. Helier, Jersey-based company said it had a loss of ...